Rein Therapeutics Net Debt Growth & History (RNTX)
Rein Therapeutics's net debt was −$12.9M for fiscal 2024.
View full Rein Therapeutics company overviewRein Therapeutics annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | −$12.9M | $4.4M | — |
| 2023 | 2023-12-31 | −$17.3M | −$12.1M | — |
| 2022 | 2022-12-31 | −$5.1M | −$1.7M | — |
| 2021 | 2021-12-31 | −$3.4M | — | — |
| 2019 | 2019-12-31 | −$278,000 | $5.0M | — |
| 2018 | 2018-12-31 | −$5.2M | — | — |
Rein Therapeutics quarterly net debt
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | $478,000 | — | — |
| Q4 2024 | 2024-12-31 | −$12.9M | $4.4M | — |
| Q4 2023 | 2023-12-31 | −$17.3M | −$12.1M | — |
| Q4 2022 | 2022-12-31 | −$5.1M | −$1.7M | — |
| Q3 2022 | 2022-09-30 | −$4.8M | $2.6M | — |
| Q2 2022 | 2022-06-30 | −$7.5M | $3.0M | — |
| Q1 2022 | 2022-03-31 | −$7.3M | $11.7M | — |
| Q4 2021 | 2021-12-31 | −$3.4M | — | — |
| Q3 2021 | 2021-09-30 | −$7.4M | −$4.3M | — |
| Q2 2021 | 2021-06-30 | −$10.5M | $1.8M | — |
| Q1 2021 | 2021-03-31 | −$19.1M | −$13.3M | — |
| Q3 2020 | 2020-09-30 | −$3.1M | −$1.4M | — |
| Q2 2020 | 2020-06-30 | −$12.3M | −$7.4M | — |
| Q1 2020 | 2020-03-31 | −$5.8M | $188,000 | — |
| Q4 2019 | 2019-12-31 | −$278,000 | $5.0M | — |
| Q3 2019 | 2019-09-30 | −$1.7M | — | — |
| Q2 2019 | 2019-06-30 | −$4.9M | — | — |
| Q1 2019 | 2019-03-31 | −$6.0M | — | — |
| Q4 2018 | 2018-12-31 | −$5.2M | — | — |
Rein Therapeutics net debt trends
Over the last five fiscal years, Rein Therapeutics's net debt decreased from −$278,000 to −$12.9M, a change of −$12.6M. The latest reported quarter, Q1 2026, shows $478,000.
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Rein Therapeutics source filings ↗